Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 2/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | RARA | P10276 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4584671 | 0.90 | ADRB3 (0.41) | MAPTADRB3KDM4ECYP1A2CYP2D6 | |
| SCHEMBL4815035 | 0.82 | MAPT (0.44) | MAPTADRB3KDM4ECYP1A2CYP2D6 | |
| SCHEMBL4584689 | 0.80 | ADRB3 (0.50) | ADRB3CYP2D6ADRB1 | |
| SCHEMBL4812068 | 0.77 | MAPT (0.44) | MAPTKDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL4583559 | 0.74 | ADRB3 (0.55) | ADRB3ADRB1 | |
| SCHEMBL4815928 | 0.73 | MAPT (0.77) | MAPTKDM4ERAB9ARARB | |
| SCHEMBL6001702 | 0.73 | MAPT (0.51) | MAPTKDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL4585841 | 0.73 | NR4A2 (0.46) | MAPTKDM4ECYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3319405 | 0.73 | CA12 (0.60) | MAPTRAB9A | |
| SCHEMBL4583289 | 0.72 | ADRB3 (0.41) | ADRB3KDM4ECYP2C9CYP2C19ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417060-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20050137236-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137236-A1 | Aminoalcohol derivatives | GPR39, PRMT9, CHRM2 | MAPT 4169/4885ADRB3 86/4885KDM4E 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.